Affiliate links are not included in CBDWorldNews editorial content.

2026 Farm Bill Moves Forward with Hemp Product Ban Intact — November Deadline Looms

House Agriculture Committee Chairman Glenn Thompson says the Farm Bill should address agriculture, not finished goods. The hemp product industry disagrees.

By CBDWorldNews Editorial Staff | April 17, 2026

The 2026 Farm Bill advanced through the House Agriculture Committee this week with its hemp provisions unchanged. The language that industry insiders have dubbed the “hemp-killing clause” — a redefinition of hemp that would effectively ban most THC drinks, edibles, and other intoxicating products — remains firmly embedded in the bill.

The provision takes effect November 12, 2026. Unless Congress acts to amend or delay it, a $180 million industry built on hemp-derived THC products will face a hard federal shutdown in less than seven months.

The November Deadline Explained

The restriction traces back to a provision tucked into the government funding package signed by the president last year. It redefined hemp to impose a ceiling of 0.4 milligrams of total THC per container for finished hemp-derived cannabinoid products.

That threshold is extraordinarily low. A single hemp-derived THC seltzer — the kind sold in bars, grocery stores, and gas stations across the country — typically contains 5 to 10 milligrams of THC. Under the new definition, those products no longer qualify as hemp. They become controlled substances.

The same applies to THC gummies, tinctures, and other edible products that make up the fastest-growing segment of the hemp market. Come November, retailers selling these products could face federal enforcement.

The Farm Bill’s Position

House Agriculture Committee Chairman Glenn Thompson has drawn a clear line. He maintains that the Farm Bill should deal with hemp as an agricultural commodity — the plant, the fiber, the seed — not with finished consumer products.

His position effectively separates hemp farming policy from hemp product regulation. For farmers growing hemp, the Farm Bill provides familiar crop support and regulatory certainty. For companies turning that hemp into consumer products, Thompson’s approach offers nothing.

Industry groups had lobbied for the committee to include language protecting compliant hemp-derived products from the November ban. Those efforts did not succeed. The Farm Bill advanced without any modifications to the product-level restrictions.

“The committee drew a line between agriculture and commerce. Hemp farmers get protection. Hemp product companies get abandoned.” — Hemp industry lobbyist speaking on background

The Delay Bill

The Hemp Planting Predictability Act, introduced in January 2026 with bipartisan support, offers the industry’s primary federal lifeline. The bill would push the November 12 effective date to November 12, 2028, giving Congress two additional years to develop a comprehensive regulatory framework.

The bill’s sponsors argue that a sudden ban would destroy businesses that operated legally under existing federal law. They point to the jobs, tax revenue, and consumer access that the hemp product market provides.

However, the delay bill faces its own challenges. It must compete for floor time with dozens of other legislative priorities. And some members of Congress view the hemp product market as a loophole that should be closed, not preserved.

The marijuana industry has also lobbied against hemp product protections. Licensed marijuana operators argue that hemp-derived THC products compete directly with their regulated products without meeting the same safety, testing, and taxation standards.

What the Industry Faces

The numbers paint a stark picture. Hemp-derived THC drinks and edibles generated an estimated $180 million in retail sales in 2025. That figure was growing rapidly before the November deadline cast a shadow over the market.

Businesses across the supply chain are now making difficult decisions. Manufacturers must choose between investing in production for products that may become illegal or scaling back and risking market share. Retailers must decide how much inventory to carry as the deadline approaches. Consumers looking for quality CBD products face uncertainty about which products will remain available.

Some companies are pivoting toward the clinical healthcare channel opened by the new Medicare CBD program. Others are reformulating products to meet the 0.4-milligram THC threshold, though that eliminates the intoxicating properties that drive consumer demand for many items.

The pet CBD market faces less direct impact since most pet products contain CBD rather than intoxicating levels of THC. But the broader regulatory uncertainty affects consumer confidence across all hemp-derived product categories.

State-Level Complications

The federal timeline interacts with state-level actions in ways that create additional confusion. Missouri is weighing its own hemp product ban. Texas just saw a court block enforcement of new hemp restrictions. Other states are considering their own regulatory frameworks.

If the federal ban takes effect in November, state-level debates become largely academic for intoxicating products. But CBD products that comply with the new THC ceiling could still face varying state regulations, creating a fragmented market.

What to Watch

Three developments will shape the hemp product market over the next seven months.

First, whether the Hemp Planting Predictability Act gains enough support for a floor vote. Without it, the November deadline stands.

Second, how the Medicare CBD program evolves. If the clinical pathway gains traction, it could demonstrate that regulated hemp-derived products serve a legitimate healthcare function — a narrative that helps the industry’s case for broader legal protection.

Third, whether courts in Texas, Missouri, and other states create precedents that constrain state-level bans. Legal victories at the state level will not override federal law, but they could build momentum for a more measured federal approach.

The clock is ticking. For hemp businesses, the Farm Bill’s advancement without product protections makes that clock louder.

These statements have not been evaluated by the Food and Drug Administration. CBD products are not intended to diagnose, treat, cure, or prevent any disease.